Table 4.
Secondary outcomes: blood and urine measures at 12 mo
| Outcome | Vitamin K Mean (SD) | Placebo Mean (SD) | Treatment Effecta (95% CI) | P |
|---|---|---|---|---|
| eGFR (ml/min per 1.73 m2) | 29 (9) | 29 (10) | 0 (−2 to 2) | 0.96 |
| Log (HOMA-IR) | 0.68 (0.79) | 0.90 (1.01) | −0.32 (−0.57 to −0.08) | 0.01 |
| Log (osteocalcin [ng/ml]) | 2.70 (0.77) | 3.62 (0.69) | −0.93 (−1.14 to −0.73) | <0.001 |
| Log (TRACP-5b [mIU/ml]) | −0.88 (1.10) | −0.76 (1.38) | −0.18 (−0.53 to 0.18) | 0.32 |
| Log (PTH [pmol/L]) | 2.46 (0.76) | 2.48 (0.69) | −0.05 (−0.20 to 0.10) | 0.50 |
| Phosphate (mmol/L) | 1.19 (0.19) | 1.19 (0.21) | 0.01 (−0.05 to 0.07) | 0.83 |
| Calcium (mmol/L) | 2.33 (0.11) | 2.32 (0.12) | 0.01 (−0.02 to 0.04) | 0.61 |
| Log (fetuin [ng/ml]) | 7.14 (0.33) | 7.22 (0.31) | 0.01 (−0.07 to 0.09) | 0.81 |
| Log (FGF-23 [RU/ml]) | 5.33 (0.71) | 5.34 (0.83) | −0.10 (−0.28 to 0.07) | 0.23 |
| Log (25OHD [nmol/L]) | 3.84 (0.63) | 3.75 (0.54) | 0.04 (−0.09 to 0.17) | 0.57 |
| Log (1,25OHD [pmol/L]) | 4.18 (0.51) | 4.14 (0.38) | 0.06 (−0.08 to 0.19) | 0.39 |
| Log (urine P-Cr ratio [mg/mmol]) | 3.85 (1.12) | 3.76 (1.54) | −0.02 (−0.49 to 0.46) | 0.95 |
HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; TRACP, Tartrate-resistant acid phosphatase; PTH, parathyroid hormone; FGF-23, fibroblast growth factor 23; 25OHD, 25-hydroxyvitamin D; 1,25OHD, 1,25-dihydroxyvitamin D; P-Cr, protein-creatinine.
a
Adjusted for age, sex, eGFR, site, and baseline values.